Kit and detection method for simultaneously detecting susceptibility genes and medication genes of Alzheimer's disease
Through nucleic acid mass spectrometry technology and single-base extension technology, the problem of difficulty in detecting multiple loci of Alzheimer's disease susceptibility gene and drug gene in the existing technology is solved, and efficient, accurate and low-cost gene detection is achieved. Meets the needs of early screening and personalized medication.
Patent Information
- Application Number
- CN202411063906.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing gene detection technology is difficult to detect multiple loci of Alzheimer's disease-related susceptible genes and drug genes simultaneously efficiently and accurately, and it is costly and complicated to operate, and it is prone to false positive or false negative results.
Using kits and detection methods based on nucleic acid mass spectrometry technology, the 25 variant sites related to AD susceptibility genes and drug genes are amplified in a single reaction system, and single-base extension technology is used, combined with time-of-flight mass spectrometry detection, and the genotype of the locus.
It realizes efficient, accurate and low-cost detection of the genotype of AD susceptible genes and drug genes, improves detection efficiency, reduces costs, meets the needs of early screening, precise prevention and personalized drug references, and has a high level of Reliability and accuracy.
Smart Images

Figure CN118995909A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of gene detection, and in particular relates to a kit and a detection method for simultaneously detecting Alzheimer's disease susceptibility genes and medication genes. Background Art
[0002] Alzheimer's disease (AD) is a central nervous system degenerative disease with an insidious onset, slow, persistent and irreversible progression. Its clinical symptoms mainly include memory loss, decreased cognitive function, and emotional and personality changes, which ultimately seriously affect daily living ability.
[0003] AD has complex heterogeneity, and genetic susceptibility and environment jointly affect its pathological process. So far, studies have reported a variety of risk genes associated with AD, including amyloid precursor protein (APP), presenilin 1 (PSEN1), presenilin 2 (PSEN2), apolipoprotein E (APOE), etc. In addition, in 2023, Jia Jianping's team identified a variant site (C.9A>T, p.T209S) of the ZDHHC21 gene in an AD family and predicted that it has strong pathogenicity. This is the first time that a new pathogenic gene for early-onset AD has been discovered by Chinese people in addition to the three known pathogenic genes (Li, W., Pang, Y., Wang, Y. et al. Aberrant palmitoylation caused by a ZDHHC21 mutation contributes to pathophysiology of Alzheimer's disease. BMC Med 21, 223 (2023). https: / / doi.org / 10.1186 / s12916-023-02930-7). The detection of susceptibility genes can provide a reference for early screening, prevention and auxiliary diagnosis of AD, and has significant application value.
[0004] At present, the AD treatment drugs approved for marketing in China include donepezil, galantamine, rivastigmine, memantine, mannitol sodium and lencanerumab. Genetic differences can cause changes in the effectiveness and toxicity characteristics of drugs. Therefore, detecting drug-related genes can provide patients with personalized medication references. For example, the effectiveness of galantamine in patients with AA genotype at the CHAT rs2177370 locus is higher than that of AG or GG genotype. In addition, the present invention innovatively incorporates the AD treatment drug "lencanerumab" approved for marketing in my country in January 2024 and the gene APOE related to its adverse reaction risk. Studies have shown that the APOE gene is related to the risk of amyloid-related imaging abnormalities in patients after taking lencanerumab. Using pharmacogenomics to detect drug-related genes and adjusting the type and dosage of drugs according to the test results can improve the cure rate and drug effectiveness of AD patients and reduce the incidence of adverse reactions.
[0005] In recent years, gene detection technology has played an important role in the study of AD, but currently these technologies are mostly used to detect susceptibility genes or medication genes separately. Integrating AD-related susceptibility genes and medication genes into a joint detection system can improve detection efficiency, reduce detection costs, and maximize the use of a single small sample. It can achieve early screening, precise prevention, auxiliary diagnosis and personalized medication reference for AD at one time, and has broad application prospects and needs.
[0006] Existing gene detection technologies, including PCR and genome sequencing, can detect AD-related susceptibility genes and medication genes to a certain extent, but there are still some problems and shortcomings. The detection efficiency of PCR technology is low, and it can only detect a few gene sites at a time. However, the detection of AD susceptibility genes and medication genes involves many sites, and PCR technology cannot meet the needs of detecting more sites at one time. Although high-throughput sequencing technology has the ability to detect multiple genes and multiple sites, it is costly, complex to operate, and time-consuming. In addition, the test results are often not accurate enough and are prone to false positive or false negative results. Therefore, to date, there is still a lack of effective and reliable analysis systems for the simultaneous detection of AD susceptibility genes and multiple genes and multiple sites related to medication. Summary of the invention
[0007] In order to solve the above problems, the present invention provides a kit and a detection method for simultaneously detecting AD susceptibility genes and medication genes based on nucleic acid mass spectrometry technology. In a single reaction system, 25 variant sites related to AD susceptibility genes and medication genes are amplified, and then single base extension is performed at the variant site, using ddNTP as the extension raw material to extend one base at the variant site. The extended product is further detected by time-of-flight mass spectrometry after desalting and purification. The molecular weight of the products extended by different sites and different mutations is different, and the speed at which they fly in the vacuum tube is different, so as to judge the size of the product molecular weight, thereby judging the genotype of the site.
[0008] In order to achieve the above object, the present invention adopts the following technical scheme:
[0009] The first aspect of the present invention provides a kit for simultaneously detecting Alzheimer's disease susceptibility genes and medication genes, comprising a detection reagent for detecting 25 mutation sites of 15 genes, wherein the 25 mutation sites of the 15 genes include 17 mutation sites of 10 susceptibility genes and 10 mutation sites of 6 medication genes, wherein the susceptibility genes and medication genes contain 2 mutation sites of one gene that are repeated;
[0010] The 17 mutation sites of the 10 susceptible genes are: rs429358 and rs7412 sites of APOE gene, rs3764650 and rs4147929 sites of ABCA7 gene, rs9331949 site of CLU gene, rs2070045 and rs1784933 sites of SORL1 gene, rs67327804 site of BIN1 gene, p.T209S site of ZDHHC21 gene, rs2234255 site of TREM2 gene, rs63750391, rs1335033402, rs63751037 and rs63749911 sites of PSEN1 gene, rs148279 0603 and rs28936379 sites, APP gene rs63750264 site; the 10 mutation sites of the 6 medication genes are: CHAT gene rs3793790 and rs2177370 sites, CHRNA7 gene rs6494223 site, BCHE gene rs1803274 site, CYP2D6 gene rs1065852, rs3892097 and rs28371725 sites, NR1I2 gene rs1523130 site, APOE gene rs429358 and rs7412 sites; the 2 mutation sites of the repeated 1 gene are: APOE gene rs429358 and rs7412 sites.
[0011] Preferably, the detection reagent includes SEQ ID NO.1 and SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6, SEQ ID NO.7 and SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, SEQ ID NO.11 and SEQ ID NO.12, SEQ ID NO.13 and SEQ ID NO.14, SEQ ID NO.15 and SEQ ID NO.16, SEQ ID NO.17 and SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO.20, SEQ ID NO.21 and SEQ ID NO.22, SEQ ID NO.23 and SEQ ID NO.24, SEQ ID NO.25 and SEQ ID NO.26, SEQ ID NO.27 and SEQ ID NO.28, SEQ ID NO.29 and SEQ ID NO.30 or SEQ ID NO.31, SEQ ID NO.32 and SEQ ID NO.33, SEQ ID NO.34 and SEQ ID NO.35, SEQ ID NO. The amplification primer pairs shown in SEQ ID NO.35 and SEQ ID NO.36, SEQ ID NO.37 and SEQ ID NO.38, SEQ ID NO.39 and SEQ ID NO.40, SEQ ID NO.41 and SEQ ID NO.42, SEQ ID NO.43 and SEQ ID NO.44, SEQ ID NO.45 and SEQ ID NO.46, SEQ ID NO.47 and SEQ ID NO.48, and SEQ ID NO.49 and SEQ ID NO.50.
[0012] Preferably, the detection reagent further comprises a single base extension primer, and the single base extension primer is shown in SEQ ID NO.51 to SEQ ID NO.75.
[0013] Preferably, the detection reagent further comprises a PCR amplification reagent cooperating with the amplification primer pair and a single base extension reaction reagent cooperating with the single base extension primer.
[0014] Preferably, the detection reagent further comprises a SAP enzyme digestion treatment reagent, and the SAP enzyme digestion treatment reagent comprises SAP Buffer and SAP Enzyme.
[0015] Preferably, the PCR amplification reagent includes 10×PCR Buffer with 20mM, 10×GC pro Buffer (0.5-1M betaine, 0.5-2% DMSO, 2% glycerol) for improving the amplification efficiency of high GC content, 25mM MgCl 2 , 25mM dNTP Mix and 5U / μl PCR Enzyme.
[0016] Preferably, the single base extension reaction reagents include iPLEX Buffer, iPLEX Termination mix and iPLEX Enzyme.
[0017] The second aspect of the present invention provides a use of the above kit in preparing a reagent for detecting Alzheimer's disease susceptibility genes and medication genes, comprising the following steps:
[0018] Step S1, preparing genomic DNA of a sample to be tested, wherein the sample to be tested is derived from human blood, saliva, oral swab or hair root;
[0019] Step S2, using the genomic DNA of the sample to be tested prepared in step S1 as a template, the amplification primers shown in SEQ ID NO.1 to SEQ ID NO.50 are mixed in one tube and then subjected to multiple PCR amplification, the amplification product is subjected to SAP enzyme digestion treatment, and then the single base extension primers shown in SEQ ID NO.51 to SEQ ID NO.75 are mixed in one tube and then subjected to single base extension reaction, after the reaction is completed, matrix-assisted laser desorption ionization time-of-flight mass spectrometry is used for detection, and finally the genotype of the detection site is analyzed by Typer software.
[0020] Preferably, in step S2, the conditions for the multiplex PCR amplification are pre-denaturation at 95°C for 2 min; denaturation at 95°C for 30 sec, annealing at 60°C for 30 sec, extension at 72°C for 60 sec, 15-20 cycles; denaturation at 95°C for 30 sec, annealing at 65°C for 30 sec, extension at 72°C for 60 sec, 25-30 cycles; post-extension at 72°C for 5 min.
[0021] Preferably, in step S2, the conditions of the single base extension reaction are pre-denaturation at 95°C for 30 seconds; denaturation at 95°C for 5 seconds, annealing at 52°C for 5 seconds, extension at 80°C for 5 seconds, for a total of 40 cycles, with 5 cycles of annealing and extension inserted in each cycle; and finally post-extension at 72°C for 3 minutes.
[0022] The third aspect of the present invention provides a method for genetic risk assessment based on susceptibility genes for Alzheimer's disease, which uses the susceptibility genes detected by the above kit to perform genetic risk assessment, comprising the following steps:
[0023] Step S1, according to the allele frequency distribution, simulate a batch of Alzheimer's disease control group and case group data, and calculate the GRS (Genetic Risk Score) score of each sample according to the EV-GRS (Explained Variance Weighted Genetic Risk Score) method, where
[0024] EV-GRS formula:
[0025]
[0026] OR (Odds Ratio) value: odds ratio, or odds ratio, especially in case-control studies and logistic regression analysis, it is used to measure the influence of a factor on the occurrence of a disease;
[0027] MAF (Minor Allele Frequency): minimum allele frequency;
[0028] Step S2, through calculation, the GRS score is less than 0.5, indicating that the control group has a major advantage;
[0029] Step S3, using the GRS score as the feature value, modeling is performed according to the machine learning model. Stratified random sampling is used for grouping. The grouping ratio can be 7:3, 4:1, etc. The present invention is modeled according to the logistic regression model, and the prediction effect is good. The AUC (Area Under the Curve) in the training set can reach 0.7275, and the AUC in the validation set can reach 0.6437.
[0030] The technical solution of the present invention has the following beneficial effects:
[0031] (1) The detection of AD susceptibility genes provided by the present invention takes into account the differences in the genetic spectrum of the Chinese population and the European and American populations, and selects 17 single nucleotide polymorphism sites that are significantly associated with the risk of AD in the Chinese population. These sites are independent of each other and do not have linkage disequilibrium. When the EV-GRS method is combined with a logistic regression model for genetic risk assessment, it shows high reliability and accuracy. Therefore, the site selection of the present invention is representative, independent, and has accumulative risk values, and can be used to assess the risk of an individual suffering from AD.
[0032] (2) The detection of AD drug genes provided by the present invention covers all AD therapeutic drugs currently marketed in my country, as well as all drug gene loci with a strong level of evidence updated in the PharmGKB database, and comprehensively covers genes related to pharmacokinetics, pharmacodynamics and adverse reactions, which can assist clinicians in formulating individualized treatment plans.
[0033] (3) The detection technology provided by the present invention can simultaneously detect AD susceptibility genes and drug genes, thereby improving detection efficiency, reducing detection costs, and maximizing the use of a single small sample. It can achieve early screening, precise prevention, auxiliary diagnosis and personalized drug reference for AD at one time, and has broad application prospects and needs.
[0034] (4) Nucleic acid mass spectrometry technology has low cost, high automation, short detection time, strong specificity, high sensitivity, and the maximum throughput of single-hole detection can reach 50 SNPs. The kit and detection method provided by the present invention can simultaneously detect 25 variant sites of AD susceptibility genes and drug-related genes using nucleic acid mass spectrometry technology, and can achieve efficient, accurate, low-cost, and rapid genotyping of the above variant sites. The detection results are stable, which has obvious advantages over traditional methods, improves the detection accuracy, helps to better understand the genetic characteristics of patients, grasp the laws and characteristics of the disease, formulate personalized treatment plans, enhance the treatment effect, and avoid the occurrence of adverse reactions. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] In order to make the purpose, technical solution and beneficial effects of the present invention clearer, the present invention provides the following drawings for illustration. The drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can also be obtained according to the method disclosed in the present invention without creative work.
[0036] Figure 1 The mass spectrometry analysis diagram of the homozygous samples before and after the optimization of the APOErs429358 site system and reaction conditions, where A is before the rs429358 site primer optimization, and B is after the rs429358 site primer optimization;
[0037] Figure 2 This is the mass spectrometry cluster analysis diagram of heterozygous samples before and after the optimization of the CYP2D6 rs1065852 site system and reaction conditions, where A is before the rs1065852 site primer optimization, and B is after the rs1065852 site primer optimization;
[0038] Figure 3 The figure is a distribution diagram of GRS scores in the control group and the case group in Example 3;
[0039] Figure 4It is a ROC (Receiver Operating Characteristic) curve diagram of the training set and the validation set of the EV-GRS logistic regression model used for genetic risk assessment of Alzheimer's disease in Example 3. DETAILED DESCRIPTION
[0040] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0041] The present invention screened the susceptibility gene loci significantly associated with AD in the Chinese population by consulting a large number of authoritative scientific research literature at home and abroad, as well as all the AD medication gene loci with strong evidence levels updated in the PharmGKB database so far, and finally selected 25 variant sites of 15 genes, including 10 genes and 17 sites of AD susceptibility genes: APOE (rs429358, rs7412), ABCA7 ((rs3764650, rs4147929), CLU ((rs9331949), SORL1 ((rs2070045, rs1784933), BIN1 ((rs67327804), ZDHHC21 ((p.T209S), TREM2 ((rs2234255), PSEN1 (rs63750391, rs1335033402, rs63751037, rs63749911), PSEN2 (rs1482790603, rs28936379), APP (rs63750264), and AD medication genes, a total of 6 genes and 10 loci: CHAT (rs3793790, rs2177370), CHRNA7 (rs6494223), BCHE (rs1803274), CYP2D6 (rs1065852, rs3892097, rs28371725), NR1I2 (rs1523130), APOE (rs429358, rs7412), of which APOE (rs429358, rs7412) is a susceptibility gene and medication gene with 1 gene and 2 loci repeated.
[0042] By designing multiple PCR primers and single base extension primers covering the above sites, combined with matrix-assisted laser dissociation adsorption time-of-flight mass spectrometry technology, efficient, accurate, low-cost and rapid detection of the sites was performed. The designed primer sequences are shown in Table 1, and the single base extension primers are shown in Table 2:
[0043] Table 1 Multiplex PCR primers
[0044]
[0045]
[0046] Table 2 Single base extension primers
[0047]
[0048]
[0049]
[0050] Reagents used in the embodiments of the present invention: Blood genomic DNA extraction kit ((DP348-02, Tiangen), Pro,PCR Reagent And Kit CPM (10x384) (Agena Bioscience, USA). Multiplex PCR primers and single base extension primers were synthesized by Shanghai Bio-Tech Co., Ltd., 5 OD per tube.
[0051] The steps of detecting Alzheimer's disease susceptibility genes and medication genes in the embodiment of the present invention mainly include:
[0052] Step 1: Sample preparation
[0053] (1) Specimen collection: Whole blood specimens are routinely collected from 5 ml of venous blood in EDTA anticoagulant tubes. The blood can be tested immediately after collection or stored at 4°C for later use.
[0054] (2) Extraction of whole blood genomic DNA: refer to the extraction instructions of the blood genomic DNA extraction kit (DP348-02, Tiangen). After extraction, the absorbance OD260 / 280 of the DNA was between 1.7 and 2.0. Then, the DNA sample was diluted to 10 ng / μL for the next PCR reaction.
[0055] Step 2: Primer dilution
[0056] (1) The primer powder for multiplex PCR amplification was dissolved in ultrapure water to prepare a 100 μM stock solution, and mixed so that the final concentration of each amplification primer was 0.5 μM;
[0057] (2) The dry powder of the extension primer is dissolved in ultrapure water to prepare a 500 μM stock solution. After mixing, the mixture is adjusted on a mass spectrometer until the peak height of each primer is relatively uniform, that is, the lowest peak height is greater than half of the highest peak height.
[0058] Step 3: Detection
[0059] (1) Multiplex PCR amplification:
[0060] Configure the following reaction system:
[0061]
[0062]
[0063] PCR amplification program: pre-denaturation at 95°C for 2 min; denaturation at 95°C for 30 sec, annealing at 60°C for 30 sec, extension at 72°C for 60 sec, 15 cycles; denaturation at 95°C for 30 sec, annealing at 65°C for 30 sec, extension at 72°C for 60 sec, 30 cycles; post-extension at 72°C for 5 min.
[0064] (2) SAP enzyme digestion treatment, prepare the following enzyme digestion reaction system:
[0065]
[0066] Add it to 5 μL of the reaction product of the first round of multiplex PCR amplification, a total of 7 μL, and perform the following reaction: incubate at 37°C for 40 min; incubate at 85°C for 5 min.
[0067] (3) Single base extension reaction: prepare the following reaction system:
[0068]
[0069]
[0070] Add it to 7 μL of the reaction product from the previous round, a total of 9 μL, and perform the following reaction: pre-denaturation at 95°C for 30 seconds; denaturation at 95°C for 5 seconds, annealing at 52°C for 5 seconds, extension at 80°C for 5 seconds, for a total of 40 cycles, with 5 cycles of annealing and extension inserted in each cycle; finally, post-extension at 72°C for 3 minutes.
[0071] (4) Mass spectrometry detection: Use a fully automatic 384-well module system (CPM384) with a chip preparation module for mass spectrometry detection. After the previous round of extension reaction, add 12 μL of ultrapure water to the product and transfer it to the chip preparation module of the nucleic acid mass spectrometer. Place a chip in the module and set the program. The machine automatically performs product desalting, chip spotting and product flight steps. After the flight, use the machine's built-in Typer software to analyze the data.
[0072] It should be noted that the primers for two loci were optimized during the test:
[0073] (1) The GC content of the sequence at the APOErs429358 site is above 75%, which makes primer amplification difficult. Using homozygous CC mutant DNA as a sample, the results obtained from the initial reaction procedure and reaction system test are as follows Figure 1As shown in A in the figure, the positive peak of C cannot be obtained. After analysis, the reason is that the primer sequence with high GC content cannot complementarily bind to the target gene sequence. Therefore, in the initial 15-20 cycles, the annealing temperature is appropriately lowered according to the primer Tm of the binding part to improve the amplification efficiency. At this time, the small amount of target fragments obtained include the 10-mer tag of the universal artificial sequence in the PCR primer and the target gene sequence with high GC content; subsequently, in order to take into account the amplification of the target gene sequence with high GC content, the annealing temperature is increased at this time so that the primer can bind more efficiently and reduce non-specific amplification. In addition, the present invention adds a GC template enhancer 10×GC pro Buffer (0.5-1M betaine, 0.5-2% DMSO, 2% glycerol) to the reaction system to significantly improve the amplification efficiency of the fragment at the APOErs429358 site. Through multiple optimizations of the system formula and reaction procedures, the ideal results were finally obtained, as shown in FIG. Figure 1 As shown in B.
[0074] (2) There is a mutation in the SNP around the CYP2D6 rs1065852 site. In the test of 20 samples with the single pair of primers originally designed, the heterozygous results in the cluster diagram shifted upward as a whole, such as Figure 2 As shown in A, the results after redesigning the primers and testing the optimization are clearly visible, as shown in Figure 2 As shown in B.
[0075] Example 1 Specificity Detection
[0076] In this example, 10 whole blood specimens were selected and verified using the kit and detection method of the present invention and the Sanger sequencing method, respectively. The verification results were 100% consistent with the present method.
[0077] Taking one of the results as an example, the results of mass spectrometry detection of the present invention are shown in Table 3 below:
[0078] Table 3 Mass spectrometry detection results
[0079]
[0080]
[0081] At the same time, the gold standard method of sequencing is as follows:
[0082] (1) The sample preparation method is the same as above;
[0083] (2) PCR amplification reagents used: Promega Go Taq Hot Start Polymerase;
[0084] (3) Primer preparation:
[0085] (a) Design specific primers for each site;
[0086] (b) 25 pairs of primers were synthesized from Shanghai Bio-Tech Co., Ltd., 5 OD per tube;
[0087] (c) Each primer was diluted to 10 μM;
[0088] PCR amplification was performed for each locus
[0089]
[0090]
[0091] (4) The PCR product was sent to Shanghai Sangon Biotechnology Co., Ltd. for sequencing. The sequencing results are shown in Table 4 below:
[0092] Table 4 Sanger sequencing test results
[0093]
[0094]
[0095]
[0096] As can be seen from Tables 3 and 4, the detection results of the Sanger sequencing method are completely consistent with the detection results of the nucleic acid flight mass spectrometry method, indicating that the detection method of the present invention has extremely high accuracy, and one-well reaction can detect all 25 sites, while the sequencing method requires 25-well reactions, and the workload and cost are much higher than this method.
[0097] Example 2 Sensitivity Detection
[0098] This example adopts the kit and detection method of the present invention, selects three DNA samples, performs gradient dilution, and the initial DNA loading amount is 10ng, 5ng, 2.5ng, 1ng, 0.5ng, 0.2ng, 0.1ng respectively, performs subsequent PCR, digestion, extension and machine test, and the statistical results of the three samples are shown in the following Tables 5-7:
[0099] Table 5 Sensitivity test results of sample 1
[0100]
[0101]
[0102] Table 6 Sensitivity test results of sample 2
[0103]
[0104]
[0105] Table 7 Sensitivity test results of sample 3
[0106]
[0107]
[0108]
[0109] The results showed that when the sample amount was as low as 0.1ng, all sites of the three samples could be correctly detected. This indicates that this kit can detect all 25 sites of 15 genes at once with as low as 0.1ng of genomic DNA, which has very high sensitivity and is also suitable for the study of complex or rare samples.
[0110] Example 3 Genetic Risk Assessment
[0111] This embodiment provides a method for genetic risk assessment based on susceptibility genes for Alzheimer's disease, which uses 17 mutation sites of 10 susceptibility genes detected by the kit of the present invention to perform genetic risk assessment, including the following steps:
[0112] Step S1, based on the allele frequency distribution, simulate a batch of 10,000 Alzheimer's disease control group and 10,000 case group data, and calculate the GRS score of each sample according to the EV-GRS method. EV-GRS takes into account both the SNP effect and the risk allele frequency (ie, the minimum allele frequency MAF).
[0113] EV-GRS formula:
[0114]
[0115] OR value: odds ratio, or odds ratio, especially in case-control studies and logistic regression analysis, it is used to measure the impact of a factor on the occurrence of a disease.
[0116] OR value calculation: A SNP site has two alleles, recorded as Allele1 and Allele2. Assuming Allele1 is the risk allele, the OR value of the risk allele is calculated according to the following formula:
[0117]
[0118] OR value of Allele 1: Odds Ratio = (A / B) / (C / D) = AD / BC.
[0119] MAF: Minimum allele frequency. MAF can be derived from public databases of previous corresponding populations, such as dbSNP, 1000Genomes project or HAPMAP project.
[0120] G represents the set vector of risk alleles of all SNP sites (Gi represents the number of risk alleles of the i-th SNP site). For the wild genotype, since it does not contain risk alleles, Gi=0; for the heterozygous mutant genotype, it contains 1 risk allele, so Gi=1; for the homozygous mutant genotype, it contains 2 risk alleles, so Gi=2.
[0121] Step S2, after calculation, the GRS score is less than 0.5, and the control group has a major advantage. The distribution of GRS scores in the control group and the case group is as follows Figure 3 shown.
[0122] Step S3, using the GRS score as the feature value, modeling is performed according to the machine learning model. Considering that random sampling may cause bias in the types of samples in the training set and the validation set, thereby affecting the final training and validation results, stratified random sampling is used for grouping, and the grouping ratio can be 7:3, 4:1, etc. This embodiment uses the GRS single-factor logistic regression model for modeling, and the prediction effect is better. The regression formula is:
[0123] logit P(D=1|G)=α+β(GRS),
[0124] The parameter values are: α=-0.1280, β=0.7748.
[0125] like Figure 4 As shown, the AUC of the model in the training set can reach 0.7275, and the AUC in the validation set can reach 0.6437. The AUC value is a value between 0 and 1, which is used to measure the evaluation ability of the model. The higher the AUC value, the better the risk evaluation ability of the model. The above AUC values prove that the susceptibility genes selected by the present invention have high reliability and accuracy for predicting Alzheimer's disease, and also prove the necessity of the kit of the present invention to select these susceptibility genes and mutation sites for detection.
[0126] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.
Claims
1. A kit for simultaneously detecting Alzheimer's disease susceptibility genes and medication genes, It is characterized in that Comprising a detection reagent for detecting 25 mutation sites of 15 genes, wherein the 25 mutation sites of the 15 genes include 17 mutation sites of 10 susceptible genes and 10 mutation sites of 6 medication genes, wherein the susceptible genes and medication genes contain 2 mutation sites of one gene that are repeated; The 17 mutation sites of the 10 susceptible genes are: rs429358 and rs7412 sites of APOE gene, rs3764650 and rs4147929 sites of ABCA7 gene, rs9331949 site of CLU gene, rs2070045 and rs1784933 sites of SORL1 gene, rs67327804 site of BIN1 gene, p.T209S site of ZDHHC21 gene, rs2234255 site of TREM2 gene, rs63750391, rs1335033402, rs63751037 and rs63749911 sites of PSEN1 gene, rs148279 0603 and rs28936379 sites, APP gene rs63750264 site; the 10 mutation sites of the 6 medication genes are: CHAT gene rs3793790 and rs2177370 sites, CHRNA7 gene rs6494223 site, BCHE gene rs1803274 site, CYP2D6 gene rs1065852, rs3892097 and rs28371725 sites, NR1I2 gene rs1523130 site, APOE gene rs429358 and rs7412 sites; the 2 mutation sites of the repeated 1 gene are: APOE gene rs429358 and rs7412 sites.
2. The kit according to claim 1, It is characterized in that The detection reagent includes SEQ ID NO.1 and SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6, SEQ ID NO.7 and SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, SEQ ID NO.11 and SEQ ID NO.12, SEQ ID NO.13 and SEQ ID NO.14, SEQ ID NO.15 and SEQ ID NO.16, SEQ ID NO.17 and SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO.20, SEQ ID NO.21 and SEQ ID NO.22, SEQ ID NO.23 and SEQ ID NO.24, SEQ ID NO.25 and SEQ ID NO.26, SEQ ID NO.27 and SEQ ID NO.28, SEQ ID NO.29 and SEQ ID NO.30 or SEQ ID NO.31, SEQ ID NO.32 and SEQ ID NO.33, SEQ ID NO.34 and SEQ ID NO.35, SEQ ID NO.36 and SEQ ID NO.
37. The amplification primer pairs shown in SEQ ID NO.35 and SEQ ID NO.36, SEQ ID NO.37 and SEQ ID NO.38, SEQ ID NO.39 and SEQ ID NO.40, SEQ ID NO.41 and SEQ ID NO.42, SEQ ID NO.43 and SEQ ID NO.44, SEQ ID NO.45 and SEQ ID NO.46, SEQ ID NO.47 and SEQ ID NO.48, and SEQ ID NO.49 and SEQ ID NO.
50.
3. The kit according to claim 2, It is characterized in that The detection reagent also includes a single base extension primer, and the single base extension primer is shown as SEQ ID NO.51 to SEQ ID NO.
75.
4. The kit according to claim 3, It is characterized in that The detection reagent also includes a PCR amplification reagent matched with the amplification primer pair and a single base extension reaction reagent matched with the single base extension primer.
5. The kit according to claim 4, It is characterized in that The detection reagent also includes a SAP enzyme digestion treatment reagent, and the SAP enzyme digestion treatment reagent includes SAP Buffer and SAP Enzyme.
6. The kit according to claim 4, It is characterized in that The PCR amplification reagents include 10×PCR Bufferwith 20mM, 10×GC pro Buffer, 25mM MgCl 2 , 25mM dNTP Mix and 5U / μl PCR Enzyme.
7. The kit according to claim 4, It is characterized in that The single base extension reaction reagents include iPLEX Buffer, iPLEX Termination mix and iPLEX Enzyme.
8. Use of the kit according to any one of claims 1 to 7 in the preparation of reagents for detecting Alzheimer's disease susceptibility genes and medication genes, It is characterized in that The steps include: Step S1, preparing genomic DNA of a sample to be tested, wherein the sample to be tested is derived from human blood, saliva, oral swab or hair root; Step S2, using the genomic DNA of the sample to be tested prepared in step S1 as a template, the amplification primers shown in SEQ ID NO.1 to SEQ ID NO.50 are mixed in one tube and then subjected to multiple PCR amplification, the amplification product is subjected to SAP enzyme digestion treatment, and then the single base extension primers shown in SEQ ID NO.51 to SEQ ID NO.75 are mixed in one tube and then subjected to single base extension reaction, after the reaction is completed, matrix-assisted laser desorption ionization time-of-flight mass spectrometry is used for detection, and finally the genotype of the detection site is analyzed by Typer software.
9. The use according to claim 8, It is characterized in that In step S2, the conditions for the multiplex PCR amplification are: pre-denaturation at 95°C for 2 min; denaturation at 95°C for 30 sec, annealing at 60°C for 30 sec, extension at 72°C for 60 sec, 15-20 cycles; denaturation at 95°C for 30 sec, annealing at 65°C for 30 sec, extension at 72°C for 60 sec, 25-30 cycles; post-extension at 72°C for 5 min; The conditions of the single base extension reaction are: pre-denaturation at 95°C for 30 seconds; denaturation at 95°C for 5 seconds, annealing at 52°C for 5 seconds, extension at 80°C for 5 seconds, for a total of 40 cycles, with 5 cycles of annealing and extension inserted in each cycle; and finally post-extension at 72°C for 3 minutes.
10. A method for genetic risk assessment based on susceptibility genes for Alzheimer's disease, It is characterized in that Genetic risk assessment is performed using the susceptibility gene detected by the kit described in any one of claims 1 to 7.
Citation Information
Patent Citations
Genetic diagnosis kit of Alzheimer's disease
CN105969885A
Primer set and kit for detecting gene mutation in alzheimer's disease
CN109234385A
SNP site combination, primer group and kit for early screening of Alzheimer's disease
CN111763728A
Primer combination and kit for detecting Alzheimer disease virulence gene mutation and APOE genotype
CN116162693A
Nucleic acid composition for detecting Alzheimer's disease gene based on time-of-flight nucleic acid mass spectrometry technology and application of nucleic acid composition
CN117230184A
Cited By
Alzheimer's disease genetic risk gene and medication gene joint detection kit and multivariable risk assessment model
CN121046528A
Primer probe combination for detecting Alzheimer's disease, product and application of primer probe combination
CN122081486A
